Palantir Slides, Vertex Pharmaceuticals Surges, DoorDash Lower Despite Earnings Beat

On this episode of Stock Movers:
- Palantir (PLTR) shares slide by the most in nearly a year after its financial results and projections failed to live up to investors’ lofty expectations. The company described rising demand for artificial intelligence software as a “ravenous whirlwind” and bumped its 2025 revenue forecast on Monday to about $3.9 billion from about $3.75 billion.
- Vertex Pharmaceuticals (VRTX) shares fall after the company reported adjusted earnings per share for the first quarter that missed expectations. Analysts are mixed about the launch of the non-opioid pain medication Journavx and Alyftrek, a triple modulator for cystic fibrosis
- DoorDash (DASH) drops after announcing two multibillion-dollar acquisitions: London-based delivery company Deliveroo Plc for £2.9 billion and hospitality tech company SevenRooms Inc. for $1.2 billion. Alongside the deals, DoorDash also issued a strong orders outlook for the current quarter and posted better-than-expected gross order value for the first three months of the year in a statement on Tuesday.

See omnystudio.com/listener for privacy information.